Global Neuromodulation Devices Market Discussed in Most Recent Research Report Published at MarketPublishers.com

30 Nov 2011 • by Natalie Aster

LONDON – Neuromodulation is one of the fastest growing sectors of the medical device market, with a global value in 2011 reaching USD 3.05 billion.

How will the neuromodulation devices market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the neuromodulation devices submarkets are growing most strongly? Who are the leading companies in the neuromodulation devices market? What are the most promising neuromodulation devices in development and when are they expected to receive market approval? Answers to all these questions and many more are available in the report.

New market research report “Neuromodulation Devices: World Market Prospects 2011-2021” prepared by Visiongain has been recently published at Market Publishers Ltd.

Report Details:

Title: Neuromodulation Devices: World Market Prospects 2011-2021
Published: October, 2011
Pages: 127
Price: US$ 2,664

The report provides a thorough examination of the global neuromodulation devices market’s prospects from 2011 to 2021.

Report Highlights:

• overview of the current neuromodulation devices market, with respect to the leading segments, products, companies and national markets;
• sales trends for the overall neuromodulation devices market;
• sales trends for the main segments, with detailed discussions of market potential;
• sales forecasts for top geographical markets (US, Japan, Germany, France, Italy, Spain, UK, China and India);
• analysis of leading companies in the neuromodulation devices market along with their marketed and pipeline products;
• analysis of the market’s future, including assessment of some products in the R&D pipeline;
• SWOT analysis;
• competition and opportunities influencing the market;
• market drivers and restraints;
• the unmet needs in the market, driving the growth;
• expert opinion including full interview transcripts.

Report Contents:

1. EXECUTIVE SUMMARY
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
  1.2.1 Chapter Outline
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Neuromodulation Devices

2. AN INTRODUCTION TO NEUROMODULATION
2.1 Neuromodulation
2.2 Techniques Used in Neuromodulation
  2.2.1 Electrical Stimulation Techniques
    2.2.1.1 Brain and Spinal Cord Therapies
    2.2.1.2 Cranial Nerve Stimulation
    2.2.1.3 Functional Electrical Stimulation
  2.2.2 Pharmacological Therapy
2.3 Application of Neuromodulation
  2.3.1 Pain
    2.3.1.1 Neuromodulation and Treatment of Pain
  2.3.2 Depression
    2.3.2.1 Neuromodulation and Treatment of Depression
  2.3.3 Epilepsy
    2.3.3.1 Neuromodulation and Treatment of Epilepsy
  2.3.4 Urological Disorders: Overactive Bladder & Urinary Incontinence
    2.3.4.1 SNS and Treatment of Urinary Incontinence
  2.3.5 Hearing Disorders: Profound Deafness
  2.3.6 Cardiac Disorders: Arrhythmias & Angina
    2.3.6.1 Neuromodulation and Treatment of Cardiac Disorders
  2.3.7 Parkinson's Disease

3. THE GLOBAL NEUROMODULATION DEVICES MARKET, 2010-2021
3.1 Scope and Limitations
3.2 Neuromodulation Devices is the Largest Segment in the Neurological Medical Devices Sector
3.3 Neuromodulation Devices Market in 2010
  3.3.1 SCS Devices Dominate the Neuromodulation Devices Market in 2010
3.4 Medtronic is the Market Leader in the Neuromodulation Devices Market
3.5 Neuromodulation Devices in the Market
3.6 Leading Companies in the Neuromodulation Devices Market, 2010
  3.6.1 Medtronic
    3.6.1.1 Medtronic Sales, 2010
    3.6.1.2 Medtronic's DBS and SCS Devices in the Market
    3.6.1.3 Medtronic's Product Pipeline
  3.6.2 St. Jude Medical (SJM)
    3.6.2.1 SJM Sales, 2010
    3.6.2.2 SJM Neuromodulation Devices in the Market
    3.6.2.3 SJM Product Pipeline
  3.6.3 Boston Scientific
    3.6.3.1 Boston Scientific Sales, 2010
    3.6.3.2 Boston Scientific Neuromodulation Devices: Marketed and Pipeline
  3.6.4 Cyberonics
    3.6.4.1 Cyberonics Sales, 2010
    3.6.4.2 Cyberonics Neuromodulation Devices: Marketed and Pipeline
  3.6.5 IntraPace
3.7 Neuromodulation Devices Market Forecast, 2011-2016
3.8 Neuromodulation Devices Market Forecast, 2016-2021
3.9 Changing Market Shares of the Leading Segments

4. SPINAL CORD STIMULATION DEVICES MARKET, 2010-2021
4.1 The US was the Largest Market for SCS Devices in 2010
4.2 Medtronic Dominated the US SCS Devices Market, Closely Followed by SJM and Boston Scientific
4.3 SCS Devices Market Forecast, 2011-2016
4.4 SCS Devices Market Forecast, 2016-2021
4.5 Competition in the SCS Market: Companies and Products
  4.5.1 Medtronic
  4.5.2 Boston Scientific
  4.5.3 St. Jude Medical
  4.5.4 Nevro

5. DEEP BRAIN STIMULATION DEVICES MARKET, 2010-2021
5.1 DBS Devices Market in 2010: Medtronic is the Only Company With an FDA Approved DBS Device
5.2 DBS Devices Market Forecast, 2011-2016
5.3 DBS Devices Market Forecast, 2016-2021
5.4 Competition in the DBS Devices Market: Companies and Products
  5.4.1 Medtronic
  5.4.2 St. Jude Medical

6. VAGUS NERVE STIMULATION DEVICES MARKET, 2010-2021
6.1 The US Contributed 81.3% of the VNS Market Sales in 2010
6.2 Majority of Sales of the VNS Devices Was for the Treatment of Refractory Epilepsy in 2010
6.3 Cyberonics Dominated the VNS Market in 2010
  6.3.1 Cyberonics is Set to Lose its Monopoly in the VNS Devices Market
6.4 VNS Devices Market Forecast, 2011-2016
6.5 VNS Devices Market Forecast, 2016-2021
6.6 Competition in the VNS Devices Market: Companies and Products
  6.6.1 Cyberonics
  6.6.2 CerebralRx (a spin-off of BioControl Medical)
  6.6.3 EnteroMedics

7. NEUROMODULATION DEVICES PIPELINE
7.1 CVRx
7.2 Apnex Medical
7.3 ImThera Medical
7.4 NeuroPace
7.5 Intelect Medical (acquired by Boston Scientific Corporation)
7.6 EnteroMedics
7.7 MetaCure
7.8 Other Companies and Products

8. LEADING NATIONAL MARKETS, 2010-2021
8.1 Leading National Markets in 2010
8.2 The US Market Forecast, 2011-2021
8.3 The Japanese Market Forecast, 2011-2021
8.4 Leading European Markets Forecast, 2011-2021
  8.4.1 The German Market
  8.4.2 The French Market
  8.4.3 The UK Market
  8.4.4 The Italian Market
  8.4.5 The Spanish Market
8.5 The Chinese Market Forecast, 2011-2021
8.6 The Indian Market Forecast, 2011-2021
8.7 Rest of the World (RoW)

9. SWOT ANALYSIS OF THE NEUROMODULATION DEVICE INDUSTRY, 2011-2021
9.1 Strengths
  9.1.1 Neuromodulation Can be Seen as Safer Than Alternative Treatments
  9.1.2 A Cost Effective Treatment Option
  9.1.3 Neuromodulation Often Means Less Medication
9.2 Weaknesses
  9.2.1 Neuromodulation Mechanisms Are Not Well Understood
  9.2.2 A Small Number of Large Companies Dominate the Market
  9.2.3 FDA Approvals
  9.2.4 Failing Clinical Trials
9.3 Opportunities
  9.3.1 Neuromodulation Market Set for Rapid Growth: Expanding Disease Indications
  9.3.2 Increasing Prevalence of Neurological Diseases
  9.3.3 The Potential of Personalised Medicine
9.4 Threats
  9.4.1 Parkinson's Disease May Soon be Treated with Stem Cells
  9.4.2 SCS Faces Competition from Other Treatment Options

10. EXPERT OPINION
10.1 Interview with Michael Berman, Founder, Berman Medical
  10.1.1 The Neuromodulation Market
  10.1.2 Challenges Facing the Neuromodulation Market
  10.1.3 Prospects for the Neuromodulation Market
10.2 Spokesperson from CVRx (Views Provided Anonymously)
  10.2.1 Barostim neo: New Implantable Device for Hypertension
  10.2.2 On the Development of Barostim neo
  10.2.3 Competition for Barostim neo
  10.2.4 On the Unmet Needs in the Market
10.3 Franck Fischer and Rebecca Kuhn, CEO and CFO, NeuroPace Inc
  10.3.1 NeuroPace's RNS Neuromodulation System for Epilepsy
  10.3.2 The Neuromodulation and the Epilepsy Markets
  10.3.3 Public Perception and Understanding of Neuromodulation
  10.3.4 Small Companies Surviving in the Industry
  10.3.5 Educating Physicians About Neuromodulation
  10.3.6 Neuromodulation's Role in Relation to Other Treatment Options
  10.3.7 Recent Healthcare Reform in the US
  10.3.8 Comparative Effectiveness Research

11. CONCLUSIONS
11.1 The Neuromodulation Devices Market is Dominated by Four Companies
11.2 The Neuromodulation Devices Market, 2011-2021
11.3 Neuromodulation Devices Will be Developed for New Indications: Driving Market Growth
11.4 Vast Opportunities for Growth in Emerging Markets
11.5 Introduction of Alternative Treatment Options Can Threaten Market Growth

APPENDIX A

APPENDIX B

VISIONGAIN REPORT EVALUATION FORM

LIST OF TABLES

LIST OF FIGURES

COMPANIES LISTED
Advanced Bionics
Advanced Neuromodulation Systems (ANS)
Aleva Neurotherapeutics
AMS group
Apnex Medical
Atrotech
Australian Therapeutic Goods Administration (TGA)
Autonomic Technologies
Avery Biomedical
Berman Medical
BioControl Medical
Biotronik
Boston Scientific
Cardiac Concepts
Cerbomed
CerebralRx
Cochlear Ltd.
Coridea
CVRx
Cyberonics
DePuy
EBR Systems
ElectroCore
EnteroMedics
Envoy Medical
Eucomed
European Commission (EC)
Food and Drug Administration (FDA)
Functional Neuromodulation
ImThera Medical
Inspire Medical Systems
Intelect Medical
International Neuromodulation Society
IntraPace
Johnson & Johnson (J&J)
Magstim
Med El
Medtronic
MetaCure
MicroTransponder
Nanoretina Inc.
National Epilepsy Foundation
Neurelec
Neurologix
Neuronetics
NeuroPace
Neuros Medical
Neurosigma
Neurotech
Neurowave Medical Technologies
Nevro
Nihon Kohden Corporation
Northstar Neuroscience
Northwestern University
Respicardia
Retina Implant AG
Second Sight Medical Products
Setpoint Medical
Spinal Modulation
SPR Therapeutics
St. Jude Medical
Synapse Biomedical
The International Neuromodulation Society
Transneuronix
Uroplasty
U.S. Centers for Disease Control (CDC)
World Health Organization

More new market research reports by the publisher can be found at Visiongain page.

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

[email protected]

MarketPublishers.com